secwatch.observer — SEC 8-K summary
======================================

Issuer:     Keros Therapeutics, Inc. (KROS)
CIK:        0001664710
Form:       8-K
Filed at:   2025-08-06T23:59:59+00:00
Accession:  0001664710-25-000068
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Keros Q2 net loss narrows to $30.7M; Board plans $375M capital return to stockholders
--------------------------------------------------------------------------------

- Net loss of $30.7M in Q2 2025 improved from $45.3M in Q2 2024, driven by Takeda license revenue.
- Cash and cash equivalents $690.2M at June 30, 2025, up from $559.9M at Dec 31, 2024.
- Board approved return of $375M excess capital to stockholders; cash runway into H1 2028.
- Lead asset KER-065 progressing toward Phase 2 trial in Duchenne muscular dystrophy starting Q1 2026.
- R&D expenses $43.5M, G&A $14.5M for Q2 2025; both increased vs year-ago period.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1664710/000166471025000068/0001664710-25-000068-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1664710/000166471025000068/kros-20250806.htm
  HTML page:      https://secwatch.observer/filing/0001664710-25-000068

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer